The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Curran, S. A.
Right arrow Articles by Winchester, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Curran, S. A.
Right arrow Articles by Winchester, R.
The Journal of Immunology, 2004, 172: 1935-1944.
Copyright © 2004 by The American Association of Immunologists

Nucleotide Sequencing of Psoriatic Arthritis Tissue before and during Methotrexate Administration Reveals a Complex Inflammatory T Cell Infiltrate with Very Few Clones Exhibiting Features That Suggest They Drive the Inflammatory Process by Recognizing Autoantigens1

Shane A. Curran*,{dagger}, Oliver M. FitzGerald{dagger}, Patrick J. Costello*,{dagger}, Jeanette M. Selby*, David J. Kane{dagger}, Barry Bresnihan{dagger} and Robert Winchester2,*

* Division of Autoimmune and Molecular Disease, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY 10032; and {dagger} Department of Rheumatology, Education and Research Center, St. Vincent’s University Hospital, Dublin, Ireland

Psoriatic arthritis is an interesting MHC class I allele associated autoimmune disease where injury is likely mediated exclusively by T cells. We used TCR {beta}-chain nucleotide sequencing to gain insight into the adaptive immune events responsible for this injury and determine whether the numerous oligoclonal expansions of this disease represent extreme determinant spreading among driving clones that recognize autoantigen or were non-Ag-driven, inflammation-related expansions. Because methotrexate suppresses but does not eliminate this inflammation, we hypothesized that clones persisting during methotrexate treatment would likely drive the inflammation. Seventy-six percent of the T cell clones in active tissue were polyclonal and unexpanded, accounting for 31% of transcripts. They were decreased greatly by methotrexate. Strikingly, most expanded clones in the inflamed joint did not persist during methotrexate treatment, were found only in inflammatory sites, exhibited no structural homology to one another, and were either CD4 or CD8 in lineage, suggesting they were non-autoantigen-driven, inflammation-related expansions. Only 12% of the expanded clones could be grouped into clonal sets distinguished by structurally homologous CDR3 {beta}-chain amino acid motifs suggesting Ag drive. These were exclusively CD8 in lineage, persisted during methotrexate administration, and were present in both joint fluid and blood implying they were candidate driver clones that recognized an autoantigen. However, a major set of putative driver clones exhibited a previously described EBV-specific {beta}-chain motif, emphasizing that the dominant feature of the disease was activation of multiple clones apparently lacking specificity for an inciting autoantigen.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. D. Wu, M. S. Maurer, R. A. Friedman, C. C. Marboe, E. M. Ruiz-Vazquez, R. Ramakrishnan, A. Schwartz, M. D. Tilson, A. S. Stewart, and R. Winchester
The Lymphocytic Infiltration in Calcific Aortic Stenosis Predominantly Consists of Clonally Expanded T Cells
J. Immunol., April 15, 2007; 178(8): 5329 - 5339.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006
Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii2 - iii15.
[Full Text] [PDF]

Home page
 J. Exp. Med.Home page
B. Meresse, S. A. Curran, C. Ciszewski, G. Orbelyan, M. Setty, G. Bhagat, L. Lee, M. Tretiakova, C. Semrad, E. Kistner, et al.
Reprogramming of CTLs into natural killer-like cells in celiac disease
J. Exp. Med., May 15, 2006; 203(5): 1343 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, et al.
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv2 - iv14.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D J Veale, C Ritchlin, and O FitzGerald
Immunopathology of psoriasis and psoriatic arthritis
Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii26 - ii29.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, et al.
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii2 - ii12.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.